Selected virologic, biochemical, and serologic endpoints at week 48, nucleoside-naive patients

	(HBeAg-positive)		(HBeAg-negative)
	Entecavir 0.5 mg (n = 354)	Lamivudine 100 mg (n = 355)	Entecavir 0.5 mg (n = 325)	Lamivudine 100 mg (n = 313)
HBV DNA*
Proportion undetectable (<300 copies/mL)	67 percent^¶	36 percent	90 percent^¶	72 percent
Mean changes from baseline (log10 copies/mL)	-6.86^¶	-5.39	-5.04^¶	-4.53
ALT normalization (≤1 X ULN)	68 percent^¶	60 percent	78 percent^¶	71 percent
HBeAg seroconversion	21 percent	18 percent	NA	NA

* Roche COBAS Amplicor PCR assay (LLOQ = 300 copies/mL).
¶ p<0.05.

Graphic 59012 Version 4.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟